Non-Small Cell Lung Cancer is a type of lung cancer that starts in the cells lining the airways and can spread to other parts of the body. When the disease is described as locally advanced, it means the tumor has grown beyond the lung but has not yet widely spread, while metastatic indicates that cancer cells have reached distant organs.
The investigational medication being studied is Rinatabart Sesutecan (Rina‑S), which is given through an intravenous infusion, a process where the medicine is delivered directly into a vein using a small needle. The purpose of the study is to assess the anti‑tumor activity of this drug when used alone. The medication is administered in a series of treatment cycles, and participants are monitored regularly for any changes in tumor size, side effects, and overall health.
During the study, tumor measurements are evaluated using the RECIST criteria, a set of simple rules that help doctors decide whether the cancer is shrinking, staying the same, or growing. Participants have scheduled visits for blood tests, imaging scans, and safety checks, allowing researchers to observe how the drug works over time and to record any adverse events that may occur.
Belgium 
France 
Germany 
Hungary 
Italy 
Poland 
Spain 
The Netherlands 
